Brought to you by 
Verastem gets rights to Infinity's duvelisib for blood cancers
07 Mar 2019
Executive Summary
Infinity Pharmaceuticals Inc. granted Verastem Inc. exclusive worldwide rights to develop and sell the Phase III blood cancer candidate duvelisib (IPI145).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Verastem gets rights to Infinity's duvelisib for blood cancers
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice